Tumor Angiogenesis

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 68919 Experts worldwide ranked by ideXlab platform

X. Chen - One of the best experts on this subject based on the ideXlab platform.

  • multimodality molecular imaging of Tumor Angiogenesis
    The Journal of Nuclear Medicine, 2008
    Co-Authors: W. Cai, X. Chen
    Abstract:

    Molecular imaging is a key component of 21st-century cancer management. The vascular endothelial growth factor (VEGF)/VEGF receptor signaling pathway and integrin αvβ3, a cell adhesion molecule, play pivotal roles in regulating Tumor Angiogenesis, the growth of new blood vessels. This review summarizes the current status of Tumor Angiogenesis imaging with SPECT, PET, molecular MRI, targeted ultrasound, and optical techniques. For integrin αvβ3 imaging, only nanoparticle-based probes, which truly target the Tumor vasculature rather than Tumor cells because of poor extravasation, are discussed. Once improvements in the in vivo stability, Tumor-targeting efficacy, and pharmacokinetics of Tumor Angiogenesis imaging probes are made, translation to clinical applications will be critical for the maximum benefit of these novel agents. The future of Tumor Angiogenesis imaging lies in multimodality and nanoparticle-based approaches, imaging of protein–protein interactions, and quantitative molecular imaging. Combinations of multiple modalities can yield complementary information and offer synergistic advantages over any modality alone. Nanoparticles, possessing multifunctionality and enormous flexibility, can allow for the integration of therapeutic components, targeting ligands, and multimodality imaging labels into one entity, termed “nanomedicine,” for which the ideal target is Tumor neovasculature. Quantitative imaging of Tumor Angiogenesis and protein–protein interactions that modulate Angiogenesis will lead to more robust and effective monitoring of personalized molecular cancer therapy. Multidisciplinary approaches and cooperative efforts from many individuals, institutions, industries, and organizations are needed to quickly translate multimodality Tumor Angiogenesis imaging into multiple facets of cancer management. Not limited to cancer, these novel agents can also have broad applications for many other Angiogenesis-related diseases.

  • Multimodality Molecular Imaging of Tumor Angiogenesis
    Journal of Nuclear Medicine, 2008
    Co-Authors: W. Cai, X. Chen
    Abstract:

    Molecular imaging is a key component of 21st-century cancer management. The vascular endothelial growth factor (VEGF)/VEGF receptor signaling pathway and integrin alpha(v)beta(3), a cell adhesion molecule, play pivotal roles in regulating Tumor Angiogenesis, the growth of new blood vessels. This review summarizes the current status of Tumor Angiogenesis imaging with SPECT, PET, molecular MRI, targeted ultrasound, and optical techniques. For integrin alpha(v)beta(3) imaging, only nanoparticle-based probes, which truly target the Tumor vasculature rather than Tumor cells because of poor extravasation, are discussed. Once improvements in the in vivo stability, Tumor-targeting efficacy, and pharmacokinetics of Tumor Angiogenesis imaging probes are made, translation to clinical applications will be critical for the maximum benefit of these novel agents. The future of Tumor Angiogenesis imaging lies in multimodality and nanoparticle-based approaches, imaging of protein-protein interactions, and quantitative molecular imaging. Combinations of multiple modalities can yield complementary information and offer synergistic advantages over any modality alone. Nanoparticles, possessing multifunctionality and enormous flexibility, can allow for the integration of therapeutic components, targeting ligands, and multimodality imaging labels into one entity, termed "nano-medicine," for which the ideal target is Tumor neovasculature. Quantitative imaging of Tumor Angiogenesis and protein-protein interactions that modulate Angiogenesis will lead to more robust and effective monitoring of personalized molecular cancer therapy. Multidisciplinary approaches and cooperative efforts from many individuals, institutions, industries, and organizations are needed to quickly translate multimodality Tumor Angiogenesis imaging into multiple facets of cancer management. Not limited to cancer, these novel agents can also have broad applications for many other Angiogenesis-related diseases.

Jan Kitajewski - One of the best experts on this subject based on the ideXlab platform.

  • Evaluating Tumor Angiogenesis.
    Methods in molecular biology (Clifton N.J.), 2012
    Co-Authors: Jessica J. Kandel, Jan Kitajewski
    Abstract:

    The evaluation of Tumor Angiogenesis in pancreatic cancers involves determining the status of Tumor vasculature and hypoxia in the Tumor. Describing the nature and extent of Tumor Angiogenesis involves evaluating the expression of endothelial and perivascular cells within the Tumor, and the expression of Angiogenesis-related genes in Tumor vasculature. Here we describe the methodology for assessment of Tumor vasculature in murine mouse models of cancer. Specifically, we provide methodology for the evaluation of Tumor hypoxia, Tumor vessel perfusion, and chromogenic and fluorescent immunohistochemistry applied to Tumor vascular analysis.

  • Notch signaling regulates Tumor Angiogenesis by diverse mechanisms
    Oncogene, 2008
    Co-Authors: J. Dufraine, Yasuhiro Funahashi, Jan Kitajewski
    Abstract:

    The Notch signaling pathway is fundamental to proper cardiovascular development and is now recognized as an important player in Tumor Angiogenesis. Two key Notch ligands have been implicated in Tumor Angiogenesis, Delta-like 4 and Jagged1. We introduce the proteins and how they work in normal developing vasculature and then discuss differing models describing the action of these Notch ligands in Tumor Angiogenesis. Endothelial Dll4 expression activates Notch resulting in restriction of new sprout development; for instance, in growing retinal vessels. In agreement with this activity, inhibition of Dll4-mediated Notch signaling in Tumors results in hypersprouting of nonfunctional vasculature. This Dll4 inhibition may paradoxically lead to increased Angiogenesis but poor Tumor growth because the newly growing vessels are not functional. In contrast, Jagged1 has been described as a Notch ligand expressed in Tumor cells that can have a positive influence on Tumor Angiogenesis, possibly by activating Notch on Tumor endothelium. A novel Notch inhibitor, the Notch1 decoy, which blocks both Dll4 and Jagged1 has been recently shown to restrict Tumor vessel growth. We discuss these models and speculate on therapeutic approaches.

W. Cai - One of the best experts on this subject based on the ideXlab platform.

  • multimodality molecular imaging of Tumor Angiogenesis
    The Journal of Nuclear Medicine, 2008
    Co-Authors: W. Cai, X. Chen
    Abstract:

    Molecular imaging is a key component of 21st-century cancer management. The vascular endothelial growth factor (VEGF)/VEGF receptor signaling pathway and integrin αvβ3, a cell adhesion molecule, play pivotal roles in regulating Tumor Angiogenesis, the growth of new blood vessels. This review summarizes the current status of Tumor Angiogenesis imaging with SPECT, PET, molecular MRI, targeted ultrasound, and optical techniques. For integrin αvβ3 imaging, only nanoparticle-based probes, which truly target the Tumor vasculature rather than Tumor cells because of poor extravasation, are discussed. Once improvements in the in vivo stability, Tumor-targeting efficacy, and pharmacokinetics of Tumor Angiogenesis imaging probes are made, translation to clinical applications will be critical for the maximum benefit of these novel agents. The future of Tumor Angiogenesis imaging lies in multimodality and nanoparticle-based approaches, imaging of protein–protein interactions, and quantitative molecular imaging. Combinations of multiple modalities can yield complementary information and offer synergistic advantages over any modality alone. Nanoparticles, possessing multifunctionality and enormous flexibility, can allow for the integration of therapeutic components, targeting ligands, and multimodality imaging labels into one entity, termed “nanomedicine,” for which the ideal target is Tumor neovasculature. Quantitative imaging of Tumor Angiogenesis and protein–protein interactions that modulate Angiogenesis will lead to more robust and effective monitoring of personalized molecular cancer therapy. Multidisciplinary approaches and cooperative efforts from many individuals, institutions, industries, and organizations are needed to quickly translate multimodality Tumor Angiogenesis imaging into multiple facets of cancer management. Not limited to cancer, these novel agents can also have broad applications for many other Angiogenesis-related diseases.

  • Multimodality Molecular Imaging of Tumor Angiogenesis
    Journal of Nuclear Medicine, 2008
    Co-Authors: W. Cai, X. Chen
    Abstract:

    Molecular imaging is a key component of 21st-century cancer management. The vascular endothelial growth factor (VEGF)/VEGF receptor signaling pathway and integrin alpha(v)beta(3), a cell adhesion molecule, play pivotal roles in regulating Tumor Angiogenesis, the growth of new blood vessels. This review summarizes the current status of Tumor Angiogenesis imaging with SPECT, PET, molecular MRI, targeted ultrasound, and optical techniques. For integrin alpha(v)beta(3) imaging, only nanoparticle-based probes, which truly target the Tumor vasculature rather than Tumor cells because of poor extravasation, are discussed. Once improvements in the in vivo stability, Tumor-targeting efficacy, and pharmacokinetics of Tumor Angiogenesis imaging probes are made, translation to clinical applications will be critical for the maximum benefit of these novel agents. The future of Tumor Angiogenesis imaging lies in multimodality and nanoparticle-based approaches, imaging of protein-protein interactions, and quantitative molecular imaging. Combinations of multiple modalities can yield complementary information and offer synergistic advantages over any modality alone. Nanoparticles, possessing multifunctionality and enormous flexibility, can allow for the integration of therapeutic components, targeting ligands, and multimodality imaging labels into one entity, termed "nano-medicine," for which the ideal target is Tumor neovasculature. Quantitative imaging of Tumor Angiogenesis and protein-protein interactions that modulate Angiogenesis will lead to more robust and effective monitoring of personalized molecular cancer therapy. Multidisciplinary approaches and cooperative efforts from many individuals, institutions, industries, and organizations are needed to quickly translate multimodality Tumor Angiogenesis imaging into multiple facets of cancer management. Not limited to cancer, these novel agents can also have broad applications for many other Angiogenesis-related diseases.

Adrian L. Harris - One of the best experts on this subject based on the ideXlab platform.

  • Inhibitors of Tumor Angiogenesis
    Cancer Drug Design and Discovery, 2014
    Co-Authors: Adrian L. Harris, Daniele G. Generali
    Abstract:

    Tumor-associated Angiogenesis is one of the essential hallmarks underlying cancer development and metastasis. Antiangiogenic agents accordingly aim to restrain cancer progression by blocking the formation of new vessels, improving the delivery of chemotherapeutic agents to the Tumor site, and reducing the shedding of metastatic cells into the circulation. The fact that the growth and spread of Tumors are dependent on Angiogenesis has led to the investigation of the role of antiangiogenic agents in the therapeutic strategies in several types of cancer. Benefits of the clinical use of direct or indirect inhibitors of Tumor Angiogenesis include an improvement of response rate and disease progression in many Tumor types, but rarely improved overall survival. This may partly be due to patient selection, since various angiogenic factors contribute to the regulation of Angiogenesis in the individual Tumor, and induced resistance may occur through induction of compensatory pathways. In the era of personalized medicine, it is of importance to properly select patients who may benefit from a specific, potentially toxic, and expensive therapy. Due to the complex nature of Tumor Angiogenesis, various biomarkers or clinical markers are still only in the development phase. In this chapter, the current data from clinical studies are reported, and possible mechanisms of Tumor resistance and predictive markers for antiangiogenic agents are summarized.

  • Notch regulation of Tumor Angiogenesis.
    Future oncology (London England), 2011
    Co-Authors: Esther Bridges, Chern Ein Oon, Adrian L. Harris
    Abstract:

    The growth of new blood vessels (Angiogenesis) is critical for Tumor growth and progression. The highly conserved Notch signaling pathway is involved in a variety of cell fate decisions and regulates many cellular biological processes, including Angiogenesis. Aberrant Notch signaling has also been implicated in Tumorigenesis. Notch ligands and receptors are expressed on many different cell types present within the Tumor, including Tumor cells and the stromal compartment. This article highlights in particular the various mechanisms by which Notch signaling can mediate Tumor Angiogenesis. The most studied Notch ligands, Delta-like 4 and Jagged1, competitively regulate Tumor Angiogenesis. Studies have demonstrated that Delta-like 4 functions as a negative regulator of Tumor Angiogenesis, whereas Jagged1 promotes Angiogenesis. Understanding the implications of Notch signaling in various Tumor backgrounds will enable the effects of specific Notch signaling inhibition on Tumor Angiogenesis and growth to be eval...

  • Markers of Tumor Angiogenesis: clinical applications in prognosis and anti-angiogenic therapy
    Investigational New Drugs, 1997
    Co-Authors: Stephen B. Fox, Adrian L. Harris
    Abstract:

    Numerous studies in many Tumor types have demonstrated that quantitation by microvessel as a measure of Angiogenesis is a powerful prognostic tool. However, the ability to exploit Tumor Angiogenesis as a prognostic marker is limited by the methods currently used for capillary identification and quantitation. This report critically evaluates all aspects of the techniques and their associated problems used for assessing Tumor Angiogenesis in tissue sections including the area of Tumor assessed, the vascular parameter measured, the method of quantitation, the stratification of patients and the practical utility of computer image analysis systems. The potential of angiogenic factors assays, proteolytic enzymes, and cell adhesion molecules as surrogate endpoints for quantifying Tumor Angiogenesis are discussed and other methods for quantifying Tumor Angiogenesis are described. The potential clinical applications of these angiogenic markers in prognosis, stratification for adjuvant treatments (both cytotoxic and anti-angiogenic/vascular targeting) and other aspects of patient management is also discussed, particularly design of phase I and II trials.

Rebecca G. Bagley - One of the best experts on this subject based on the ideXlab platform.

Related terms

Tumor Angiogenesis - 15 days free trial to Access Experts & Abstracts